ScreenerHero

GERNGeron Corporation

NAS · US · Healthcare · Biotechnology · geron.com
1.520USD-4.40%Mkt Cap: 976.56M $P/E: —

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap976.56M $
Enterprise Value817.13M $
Revenue (TTM)204.56M $
Gross Profit179.14M $
Net Income (TTM)-83.50M $
Revenue/Share0.3060 USD
Last Price1.520 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees258
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS3741631036
Valuation
P/E (Trailing)—
P/E (Forward)38.75
PEG—
EV/EBITDA-23.48
EV/Revenue3.99
P/S4.87
P/B4.56
EPS (TTM)-0.11
EPS (Forward)0.04
52W Range
1.04049% of range2.010
52W High2.010 USD
52W Low1.040 USD
Profitability
Gross Margin97.42%
Oper. Margin-22.01%
EBITDA Margin-17.01%
Profit Margin-45.41%
ROE-36.97%
ROA-14.64%
Growth
Revenue Growth17.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-111.04M $
CapEx (TTM)49.00K $
FCF Margin-38.31%
FCF Yield-8.03%
Net Debt-178.70M $
Net Debt/EBITDA5.14
Balance Sheet
Debt/Equity0.54
Current Ratio6.92
Quick Ratio5.04
Book Value/Sh0.3400 USD
Cash/Share0.4680 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1058:1000
Split DateJul 22, 2014
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.250 USD
Upside (mean)+179.6%
Target Range3.000 USD – 6.000 USD
$3.000+179.6% to mean$6.000
# Analysts4
Ownership
Shares Out.642.47M
Float556.32M
Insiders0.08%
Institutions76.57%
Short Interest
Short Ratio8.4d
Short % Float11.98%
Short % Out.11.97%
Shares Short76.81M
Short (prev mo.)80.22M
Technical
SMA 501.403 (+8.4%)
SMA 2001.417 (+7.3%)
Beta0.59
S&P 52W Chg18.16%
Avg Vol (30d)9.91M
Avg Vol (10d)8.09M
Technical Indicators
RSI (14)53.2
MACD0.0427
MACD Signal0.0394
MACD Hist.+0.0033
BB Upper1.681 USD
BB Middle1.473 USD
BB Lower1.264 USD
BB Width28.32%
ATR (14)0.0983 USD
Vol Ratio (20d)0.40x